EP4504203A1 — Therapeutic combination of kras g12c inhibitor and tead inhibitor
Assigned to Sanofi SA · Expires 2025-02-12 · 1y expired
What this patent protects
The invention relates to a therapeutic combination comprising at least one KRAS G12C inhibitor and at least one specific TEAD inhibitor selected from the group consisting of molecules of formula (III), indole compounds of formula (IV), indane compounds of formula (V) and the phar…
USPTO Abstract
The invention relates to a therapeutic combination comprising at least one KRAS G12C inhibitor and at least one specific TEAD inhibitor selected from the group consisting of molecules of formula (III), indole compounds of formula (IV), indane compounds of formula (V) and the pharmaceutically acceptable salts thereof; and to its use in the treatment of KRAS G12C-mediated cancer, in particular of lung, pancreatic or colorectal cancer. The present invention also concerns a pharmaceutical composition comprises this therapeutic combination and a kit.
Drugs covered by this patent
- Lumakras (SOTORASIB) · Amgen
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.